20 results about "Mannose receptor" patented technology

The invention belongs to the field of traditional Chinese medicines, and particularly relates to an inhalation type pharmaceutical composition for treating inflammatory respiratory diseases and a preparation method thereof. The inhalation type pharmaceutical composition comprises an active component and a nano-liposome, and mannose is modified on the surface of the nano-liposome; the active ingredients comprise bulbus fritillariae cirrhosae total alkaloids and platycodin D; the nano-liposome is prepared from the following raw materials: phospholipid, cholesterol and cholesterol-polyethylene glycol 1000-mannose ester. The liposome can be specifically recognized by a mannose receptor highly expressed on the surface of alveolar macrophage through a surface-modified mannose ligand, so that the receptor-mediated endocytosis is started, and the wrapped bulbus fritillariae cirrhosae total alkaloids and platycodin D are efficiently introduced into cells. The inhaled pharmaceutical composition of the present invention collectively pushes macrophages from a pro-inflammatory M1 phenotype to a repairable M2 phenotype. Therefore, the overall curative effect of the combination of the two components is far better than that of the independent use of any component.

The invention relates to the field of pharmaceutical preparations, in particular to mannose-modified CPD12C15 lipid nanoparticles and application of the mannose-modified CPD12C15 lipid nanoparticles in preparation of anti-gastric cancer drugs. The mannose modified CPD12C15 lipid nanoparticle disclosed by the invention is prepared from CPD12C15, phospholipid, mannose modified DSPE-PEG2000 (Distearoyl Pyrrolidone-Polyethylene Glycol 2000) and a surface active agent, wherein the CPD12C15 is encapsulated in the lipid nanoparticle, and the mannose part of the mannose modified DSPE-PEG2000 is exposed on the surface of the lipid nanoparticle; the problems that CPD12C15 is poor in water solubility, low in-vivo stability, low in bioavailability and the like are solved, meanwhile, by means of specific binding of mannose and a mannose receptor over-expressed on the surface of gastric cancer cells, active targeting delivery of drugs to tumor cells is achieved, and the drug delivery efficiency is improved. And a new thought and an experimental basis are provided for clinical application of CPD12C15 in gastric cancer treatment.

In various embodiments tolerogenic nanoparticles are provided that induce immune tolerance to one or more desired antigen(s) and / or that reduce an immune response to those antigen(s). In certain embodiments the tolerogenic nanoparticle comprises a nanoparticle comprising a biocompatible polymer; an antigen disposed within or attached to said biocompatible polymer where said antigen comprises an antigen to which immune tolerance is to be induced by administration of said tolerogenic nanoparticle to a mammal; and a first targeting moiety that binds to a scavenger receptor in the liver, and / or a second targeting moiety that binds to a mannose receptor in the liver, and / or a third targeting moiety that binds to hepatocytes, wherein said first and / or second and / or third targeting moiety are attached to the surface of said nanoparticle.

The application discloses a kind of Man-PFH-ICG@PLGA nanoparticles and preparation method and application thereof, belong to composite material preparation technical field.The application uses PLGA as carrier, using polylactic acid-glycolic acid (PLGA) nanoparticles (NPs) to mark the surface of it with mannose, and ICG and oxygen-carrying PFH are embedded therein, the obtained Man-PFH-ICG@PLGA nanoparticles have excellent targeting effect on the overexpression of mannose receptor on the surface of tumor cells, significantly promote the effective endocytosis of cells in vitro and tumor enrichment in vivo, directly relieve the hypoxic environment of tumor;It can also supplement oxygen by endogenous, to activate the TRPA1 channel overexpressed on the surface of tumor cells by ROS generated by cells, so as to inhibit cell respiration, reduce oxygen consumption, indirectly relieve the hypoxic environment of tumor, effectively inhibit the growth of tumor cells, and provide a new idea for clinical exploration of antitumor therapy.

The invention provides a kaempferol nano drug delivery system which comprises PLGA (poly (lactic-co-glycolic acid)), kaempferol and mannose, a drug is entrapped by the PLGA to form PLGA microspheres, and the surfaces of the PLGA microspheres are coupled with mannose nano-particles with a targeting function through an amide reaction; the invention protects the application of the kaempferol nano drug delivery system in rheumatoid arthritis. The kaempferol nano drug delivery system is a nano drug delivery system with a mannose receptor targeting characteristic. The invention relates to the field of targeted drugs, in particular to a kaempferol nano drug loading system which is a drug loading system for treating rheumatoid arthritis. The drug loading system for treating rheumatoid arthritis provided by the invention not only has higher encapsulation efficiency and drug loading capacity, but also is lower in preparation cost, also has excellent biocompatibility and biological safety, and has a more excellent anti-rheumatoid arthritis effect.

This invention belongs to the field of biomedicine and specifically relates to an antigen-capturing and mannose receptor-targeting nanodrug, its preparation method, and its application. This nanodrug can capture tumor-associated antigens released after thermal ablation of cancer cells and, in combination with an FTO inhibitor, deliver them to tumor-infiltrating dendritic cells. After thermal ablation, the synergistic effect of the nanodrug and immune checkpoint blockade therapy inhibits distal tumor growth and improves long-term survival.

Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

Provided herein are mannose receptor ligand-containing compounds, methods of delivering said compounds to subjects, and methods of treating diseases (e.g., central nervous system diseases) and symptoms thereof in a subject using said compounds.

The application discloses a carrier and nano drug delivery system for co-targeting tumor cells and M2 type macrophages and a preparation method thereof, wherein the carrier is a mannose-arginine-polystyrene carrier formed by chemical bonding of mannose and arginine-polystyrene. The mannose-arginine-polystyrene nano drug delivery system with the characteristics of mannose receptor targeting and micelle self-assembly is synthesized by combining mannose and arginine-polystyrene, and then two drugs with relatively large differences in physical and chemical properties are co-loaded by using physical encapsulation and electrostatic combination.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.

The application discloses a preparation method of a composite material, which comprises the following steps: S1, obtaining mesoporous silica, adding dopamine, and allowing the dopamine to self-polymerize on the surface of the mesoporous silica; S2, adding a silver source into the reaction system of S1, and carrying out chelation reaction with the polydopamine; S3, adding polylysine into the reaction system of S2; and S4, adding mannose into the reaction system of S3, carrying out coupling reaction with the polydopamine-polylysine, and forming a silver nanoparticle loaded mannose coupled polydopamine-polylysine modified mesoporous silica material. The loading of the polylysine can improve the in-vivo bioavailability and has a broad-spectrum antibacterial performance; the introduction of the mannose coupling can be coupled to the micro-nano material as a target recognition molecule, so that the toxicity generated by off-target is reduced. By utilizing the characteristics that mycobacterium tuberculosis surface highly expresses CD206 receptors, i.e., mannose receptors, and based on the bactericidal effect of silver nanoparticles and Schiff bases, an anti-tuberculosis system of the composite material is constructed.

This invention discloses the application of fullerene nanomaterials targeting mannose receptors in the preparation of drugs for treating hepatic steatosis. This invention involves an amidation reaction to attach mannose molecules to fullerenes, preparing fullerene-mannose derivative materials with defined molecular structures. By targeting the mannose receptors overexpressed by macrophages with mannose groups, this method achieves efficient uptake of these fullerene materials by macrophages, fully leveraging the superior antioxidant and anti-inflammatory properties of fullerenes, effectively reducing the expression of inflammatory factors in macrophages, and achieving effective treatment for hepatic steatosis.

The application discloses a fullerene nanomaterial capable of targeting a mannose receptor and a preparation method thereof. The application connects a mannose molecule to a fullerene through an amidation reaction to prepare a fullerene-mannose derivative material with a determined molecular structure. The mannose group targets a mannose receptor overexpressed by a macrophage, so that the fullerene material is efficiently taken by the macrophage, and the superior antioxidant and anti-inflammatory properties of the fullerene are fully exerted in the cell.

Aspects of the present disclosure include methods for modulating macrophage activity. Methods according to certain embodiments include contacting a macrophage with a mannose receptor (CD206) binding agent in a manner sufficient to modulate activity of the macrophage. Methods for converting a phenotype of a macrophage from an M2 phenotype to an M1 phenotype are also provided. Methods for inhibiting growth of a CD206-expressing cell as well as methods for treating a subject for a neoplastic condition (e.g., cancer) or a condition associated with chronic inflammation are described. Immuno-modulating peptides suitable for use in the subject methods are also presented.

The application belongs to the technical field of medicines, and particularly relates to a medicine preparation for reversing cisplatin drug resistance of ovarian cancer and a preparation method thereof; wherein the medicine preparation for reversing cisplatin drug resistance of ovarian cancer comprises the following raw materials in parts by weight: 5-15 parts of cisplatin and 80-100 parts of a lipid film; the synergistic effect of upstream and downstream pathway blockage formed by the SPHK1 inhibitor and the S1PR1 antagonist is combined with cisplatin, which directly enhances the killing of the chemotherapy drug on the drug-resistant cells, reduces the drug resistance by improving the tumor immune microenvironment through reducing the immunosuppressive macrophages, and realizes more efficient reversal of cisplatin drug resistance. A double-targeted delivery system is constructed in the lipid film: folate can specifically recognize the folate receptor highly expressed by the ovarian cancer cells, and mannose targets the mannose receptor on the surface of the M2 type macrophages, so that the drug is double-enriched in the tumor cells and the tumor microenvironment.

The invention relates to oligonucleotide agents capable of suppressing the expression of Mannose Receptor C-Type 2 (MRC2) and their use for treating lymphedema.

The invention relates to oligonucleotide agents capable of suppressing the expression of Mannose Receptor C-Type 2 (MRC2) and their use for treating lymphedema.

The invention belongs to the technical field of medicines, and particularly relates to a medicinal preparation for reversing cisplatin resistance of ovarian cancer and a preparation method of the medicinal preparation. The pharmaceutical preparation for reversing the cisplatin resistance of the ovarian cancer comprises the following raw materials in parts by weight: 5-15 parts of cisplatin and 80-100 parts of a lipid film, an SPHK1 inhibitor and an S1PR1 antagonist are adopted to form a synergistic effect of upstream and downstream pathway blocking, and are combined with cis-platinum for use, so that killing of chemotherapeutic drugs on drug-resistant cells is directly enhanced, tumor immune microenvironment is improved by reducing immunosuppressive macrophages, drug resistance is reduced, and more efficient reversal of cis-platinum drug resistance is realized. Folic acid can specifically recognize folic acid receptors highly expressed by ovarian cancer cells, and mannose is combined with mannose receptors on the surfaces of M2 type macrophages in a targeted manner, so that drugs are doubly enriched in tumor cells and tumor microenvironments.

The invention discloses a method for detecting the activity of glucocerebrosidase drugs based on cell intake, and the method comprises the following steps: (a) enabling cells to intake glucocerebrosidase drugs, and enabling the cells to overexpress mannose receptors; (b) removing the drug which is non-specifically bound outside the cells; (c) lysing the cells; and (d) carrying out enzyme specific activity detection on the lysate.

The present disclosure provides compositions comprising mannose-fused antigens to target mannose receptors. The compositions may be used to prevent immunity or reduce an immune response protein-based drugs that would otherwise elicit an immune response.